<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00362518</url>
  </required_header>
  <id_info>
    <org_study_id>04-319</org_study_id>
    <secondary_id>7-04-CR-41</secondary_id>
    <nct_id>NCT00362518</nct_id>
  </id_info>
  <brief_title>Vitamins C and Vitamin E and Cardiovascular Risk</brief_title>
  <official_title>Vitamin C and Vitamin E Therapy in Type 2 Diabetes and Cardiovascular Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of New Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Diabetes Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of New Mexico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study will examine the hypothesis that vitamin C and vitamin E given to type 2&#xD;
      diabetic individuals will provide effective anti-inflammatory, anti-thrombotic, and&#xD;
      anti-oxidative atherosclerotic protection when administered at the optimal dose as determined&#xD;
      by surrogate markers of inflammation, hypercoagulability, and oxidation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This American Diabetes Association research project is to determine why there are discrepant&#xD;
      results between individual studies of Vitamin E and C in both animals and humans compared&#xD;
      with the results obtained in large randomized human trials using Vitamin E.&#xD;
&#xD;
      Subjects: The study will enroll subjects (both men and women) with type 2 diabetes of at&#xD;
      least six months duration. An outpatient screening test will utilize the following: a&#xD;
      complete history and physical examination, an EKG, a urine hcG (only for women of&#xD;
      childbearing age), and the following blood tests: CBC, Chem-20, lipid profile, hemoglobin&#xD;
      A1C, and C-peptide stimulation test. Subjects will be excluded if they have known vascular&#xD;
      disease, uncontrolled hypertension (&gt;140/90 mmHg) or marked hyperlipidemia (serum low density&#xD;
      lipoprotein &gt; 4.1 mmol/L or serum triglycerides &gt; 7.8 mmol/L). Eligible patients must have&#xD;
      normal electrocardiogram tracings and normal screening test results (described above). Other&#xD;
      important exclusion criteria are cigarette smoking, volunteers taking Coumadin, and recent&#xD;
      use of antioxidant supplements or aspirin. All patients will provide written informed consent&#xD;
      before enrollment as approved by the University of New Mexico Human Research Review&#xD;
      Committee.&#xD;
&#xD;
      Surrogate Markers: Based on our preliminary data and the published medical literature, it is&#xD;
      extremely likely that vitamins C and E will modify all three contributors to atherosclerosis:&#xD;
      Oxidative stress, Hypercoagulability, and Inflammation. Therefore, as shown in the table&#xD;
      above, we have included standard surrogate markers for all three of these contributors.&#xD;
&#xD;
      Specific Aim: Determine the optimal oral dose of vitamin C and vitamin E relative to the&#xD;
      consumption of an atherogenic high fat supper in type 2 diabetic individuals. These data are&#xD;
      necessary in order to design prospective clinical trials in which vitamins are given to&#xD;
      prevent or delay atherosclerotic events. One reason that published clinical trials&#xD;
      demonstrate conflicting results may be the different dosages of vitamins that have been&#xD;
      utilized. In the following study, we will utilize our high fat (simulated Big Mac) meal to&#xD;
      assess the beneficial effects of these vitamins on surrogate markers of atherosclerosis.&#xD;
      Three dosages of vitamins will be utilized in order to determine the optimal dosage.&#xD;
&#xD;
      The three dosages to be tested are 1) low dose - vitamin C 250mg, vitamin E 200 IU 2) medium&#xD;
      dose - vitamin C 500 mg, vitamin E 400 IU and 3) high dose - vitamin C 1000mg, vitamin E 800&#xD;
      IU. The results will be compared to a control meal study in which only placebo (hence, no&#xD;
      vitamins) is administered. The vitamins will be administered before breakfast on each study&#xD;
      day.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The goal is to determine the effects of the vitamin C and vitamin E on surrogate markers of atherosclerosis following an atherogenic meal in type 2 diabetes</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine changes in surrogate markers of atherosclerosis in type 2 diabetes</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Study Arm A - Control: no vitamins (placebo only).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study Arm B - Low Dose: Vitamin C 250 mg, Vitamin E 200 IU</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study Arm C - Medium Dose: Vitamin C 500 mg, Vitamin E 400 IU</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study Arm D - High Dose: Vitamin C 1000 mg, Vitamin E 800 IU.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Study Arm A</intervention_name>
    <description>Control: no vitamins (placebo only). This study will provide baseline metabolic and surrogate marker changes that are caused by the high fat meal. Study arms B, C, and D will be statistically compared to this study.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Study Arm B</intervention_name>
    <description>This study arm will provide information on the response of atherogenic surrogate markers to a high fat supper when a low dosage form of vitamin C is administered (250 mg) and Vitamin E (200 IU).</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Study Arm C</intervention_name>
    <description>This study arm will provide information on the response of atherogenic surrogate markers to a high fat supper when a medium dosage form of vitamin C administered (500 mg)and Vitamin E (400 IU).</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Study Arm D</intervention_name>
    <description>This study arm will provide information on the response of atherogenic surrogate markers to a high fat supper when a high dosage form of vitamin C is administered (1000 mg) and Vitamin E (800 IU).</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The study will enroll subjects, both men and women with type 2 diabetes of at least&#xD;
             six months duration. The age of enrolled subjects will range from 21-60 years old. An&#xD;
             HbA1c blood test must show that the person's diabetes is under control. Eligible&#xD;
             subjects must have normal electrocardiogram tracings and normal hematological,&#xD;
             electrolyte and liver laboratory results at screening. Females of childbearing age&#xD;
             must agree to use an effective form of birth control throughout the study period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects will be excluded if they have known vascular disease, uncontrolled&#xD;
             hypertension (&gt;140/90 mmHg), marked hyperlipidemia (serum low density lipoprotein &gt;&#xD;
             4.1 mmol/L or serum triglycerides &gt; 7.8 mmol/L), and a body mass index greater than 40&#xD;
             kg/m2 (range 27-40). Other important exclusion criteria are cigarette smoking,&#xD;
             volunteers taking Coumadin, and recent use of antioxidant supplements or aspirin.&#xD;
             Females who are pregnant or breastfeeding will be excluded. People cannot participate&#xD;
             in this study if they are taking medications (other than antidiabetic medications)&#xD;
             which may affect blood sugar.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David S Schade, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of New Mexico School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of New Mexico Health Sciences Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <study_first_submitted>August 9, 2006</study_first_submitted>
  <study_first_submitted_qc>August 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2006</study_first_posted>
  <last_update_submitted>September 2, 2008</last_update_submitted>
  <last_update_submitted_qc>September 2, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 4, 2008</last_update_posted>
  <responsible_party>
    <name_title>David S. Schade</name_title>
    <organization>University of New Mexico</organization>
  </responsible_party>
  <keyword>atherosclerosis</keyword>
  <keyword>vitamin C</keyword>
  <keyword>vitamin E</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

